MarketCap
Milestone Scientific MLSS
$ 0.47
1.08%
Facebook
X
Telegram
Milestone Scientific Income Statement 2025-2009 | MLSS
Brief overview of financial results at Milestone Scientific
The comparison covers a five-year financial horizon. Revenue reported by Milestone Scientific was 5.4 million dollars at the beginning of the period and 9 million dollars at the end. Overall revenue changed by +65%, equal to an annualized rate of about 10.5%. The company expanded its sales base at a healthy rate.
Gross profit was $3.6 million at the start and $6.4 million at the end of the period (+76.9%). Cost of revenue developed more favorably than sales, supporting gross profitability. The gross margin was 66.6% at the start and 71.4% at the end. The business retained more gross profit from each unit of revenue.
The operating result measured by EBITDA moved from −7.4 million dollars to −5.6 million dollars, or +24.2%. The operating result developed less favorably than sales. EBITDA margin was −136.3% at the start and −62.6% at the end. The increased EBITDA share is a positive sign.
The final result was −$7.4 million initially and −$5.7 million in the final year. The loss reduction is constructive, but the recovery is incomplete.
Market capitalization changed from $178 million to $23.8 million (−86.6%). The market has not yet confirmed the improvement in fundamentals.
Overall conclusion
The financial profile remains mixed, with strengths and risks moving in different directions. The strongest signals are an improving EBITDA margin, revenue expansion and a stronger final result. The overall view is constrained by a low EBITDA margin and declining capitalization. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Milestone Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
23.8 M | 69.4 M | 45.1 M | 65 M | 88.8 M | 178 M | 80.5 M | 14.1 M | 32.4 M | 33.7 M | 36.6 M | 54.6 M | 25.7 M | 20.1 M | 7.59 M | 18.6 M | - |
Shares |
82.1 M | 79.8 M | 72.8 M | 70.6 M | 68.8 M | 63.1 M | 45.7 M | 35.3 M | 32.7 M | 27 M | 21.4 M | 20.1 M | 17.1 M | 16.1 M | 15.2 M | 14.9 M | - |
Historical Prices |
0.29 | 0.87 | 0.62 | 0.92 | 1.29 | 2.82 | 1.74 | 0.4 | 0.95 | 1.2 | 1.71 | 2.72 | 1.5 | 1.2 | 0.41 | 1.25 | 0.65 |
Net Income |
-5.72 M | -4.71 M | -6.93 M | -8.71 M | -6.82 M | -7.39 M | -7.52 M | -7.43 M | -5.19 M | -5.95 M | -5.47 M | -1.7 M | 1.46 M | -870 K | -1.48 M | -615 K | - |
Revenue |
8.97 M | 8.63 M | 9.83 M | 8.81 M | 10.3 M | 5.44 M | 8.37 M | 9.62 M | 11.3 M | 10.5 M | 9.49 M | 10.3 M | 10 M | 8.65 M | 8.38 M | - | - |
Cost of Revenue |
2.57 M | 2.2 M | 3.03 M | 3.91 M | 3.99 M | 1.82 M | 2.66 M | 5.19 M | 4.31 M | - | - | - | - | - | - | - | - |
Gross Profit |
6.41 M | 6.43 M | 6.79 M | 4.9 M | 6.31 M | 3.62 M | 5.72 M | 4.43 M | 6.97 M | 6.31 M | 6.44 M | 6.7 M | 6.81 M | 5.59 M | 5.36 M | 6.22 M | - |
Operating Income |
-5.7 M | -6.76 M | -7.11 M | -8.83 M | -7.38 M | -7.45 M | -4 M | -8 M | -5.23 M | -6.51 M | -3.06 M | -790 K | 1.09 M | -520 K | -1.22 M | -701 K | - |
Interest Expense |
- | 60.3 K | 126 K | 54.6 K | -16.4 K | -24.8 K | -10.4 K | -7.23 K | -4.93 K | -5.09 K | -5.35 K | 2.67 K | 70.8 K | 176 K | 132 K | 95.1 K | - |
EBITDA |
-5.62 M | -6.72 M | -7.04 M | -8.76 M | -7.3 M | -7.41 M | -3.74 M | -5.58 M | -4.66 M | -6.35 M | -2.96 M | -694 K | 1.18 M | -425 K | -1.12 M | -656 K | - |
Operating Expenses |
12.1 M | 13.2 M | 13.9 M | 13.7 M | 13.7 M | 11.1 M | 9.72 M | 10.9 M | 12.2 M | 12.8 M | 9.5 M | 7.49 M | 5.73 M | 6.11 M | 6.59 M | 6.92 M | - |
General and Administrative Expenses |
11.6 M | 12.3 M | 13.1 M | 12.5 M | 12.7 M | 10.8 M | 9.53 M | 10.6 M | 11.9 M | 11.5 M | 9.4 M | 7.4 M | 5.53 M | 5.93 M | 6.45 M | 6.65 M | - |
All numbers in USD currency
Quarterly Income Statement Milestone Scientific
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
82 M | 85 M | - | 82.3 M | 82 M | 81.9 M | 78 M | 80 M | 80 M | 79.7 M | 75.8 M | 73.7 M | 72.3 M | 72.1 M | 69.3 M | 71 M | 70.4 M | 69 M | 68.1 M | 69.6 M | 69.2 M | 66.6 M | 64.1 M | 65.8 M | 56.7 M | 49.7 M | 49.4 M | 47.7 M | 45.4 M | 40.5 M | 33.8 M | 35.6 M | 35.3 M | 34.8 M | 33.2 M | 33.6 M | 32.4 M | 32 M | 30.4 M | 29.2 M | 26 M | 22.6 M | 21.7 M | 21.4 M | 22.4 M | 21.9 M | 21.4 M | 21.2 M | 20.2 M | 17.8 M | 17.7 M | 17.3 M | 16.7 M | 16.4 M | 16.5 M | 16.2 M | 16 M | 15.3 M | 15.5 M | 15.1 M | 15 M | 15.5 M |
Net Income |
-1.99 M | -840 K | - | -1.15 M | -1.48 M | -1.99 M | - | -1.46 M | 224 K | -1.44 M | - | -1.47 M | -2.22 M | -1.31 M | - | -1.97 M | -2.86 M | -1.92 M | - | -2.04 M | -2.7 M | -986 K | - | -1.49 M | -3.17 M | -1.6 M | - | -2.84 M | -1.04 M | -783 K | - | -4.39 M | -1.34 M | -1.87 M | - | -1.41 M | -1.48 M | -505 K | - | -1.7 M | -1.59 M | -750 K | - | -1.57 M | -2.07 M | -419 K | - | -358 K | -169 K | 195 K | - | 1.46 M | 74 K | 151 K | - | 15.2 K | -165 K | -355 K | - | -637 K | -298 K | -142 K |
Revenue |
2.32 M | 2.16 M | - | 2.36 M | 2.32 M | 2.23 M | - | 2.51 M | 1.85 M | 2.25 M | - | 2.06 M | 2.91 M | 2.6 M | - | 2.22 M | 1.65 M | 2.7 M | - | -69.9 K | -95.9 K | 1.3 K | - | - | - | 1.81 M | - | 49.1 K | 58.7 K | 9.56 K | - | 259 K | 78.6 K | 36.8 K | - | 2.85 M | 15.5 K | -44.4 K | - | -253 K | -57.9 K | -270 K | - | -711 K | -690 K | -358 K | - | -224 K | -213 K | 2.62 M | - | -212 K | -47.1 K | 2.49 M | - | - | -46.1 K | -78.1 K | - | -60 K | - | - |
Cost of Revenue |
706 K | 598 K | - | 719 K | 706 K | 585 K | - | 678 K | 443 K | 573 K | - | 556 K | 1.02 M | 708 K | - | 763 K | 968 K | 1.02 M | - | 748 K | 1.06 M | 1.12 M | - | 410 K | 55.6 K | 527 K | - | 524 K | 752 K | 619 K | - | 1.74 M | 1.02 M | 563 K | - | 1.04 M | 874 K | 1.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
1.62 M | 1.56 M | - | 1.64 M | 1.62 M | 1.65 M | - | 1.84 M | 1.41 M | 1.68 M | - | 1.5 M | 1.89 M | 1.89 M | - | 1.45 M | 681 K | 1.68 M | - | 1.36 M | 1.37 M | 1.8 M | - | 836 K | 112 K | 1.28 M | - | 1.38 M | 1.51 M | 1.3 M | - | -120 K | 1.41 M | 1.24 M | - | 1.81 M | 1.65 M | 2.29 M | - | 1.67 M | 1.58 M | 2.2 M | - | 1.67 M | 1.2 M | 1.84 M | - | 1.71 M | 1.59 M | 1.74 M | - | 1.77 M | 1.53 M | 1.68 M | - | 1.5 M | 1.47 M | 1.26 M | - | 1.15 M | 1.6 M | 1.55 M |
Operating Income |
-1.48 M | -828 K | - | -1.13 M | -1.48 M | -2 M | - | -1.47 M | -1.78 M | -1.47 M | - | -1.51 M | -2.28 M | -1.34 M | - | -2.01 M | -2.88 M | -1.91 M | - | -1.98 M | -2.87 M | -984 K | - | -1.48 M | -3.17 M | -1.61 M | - | -947 K | -1.11 M | -818 K | - | -4.55 M | -1.42 M | -2 M | - | -1.41 M | -1.55 M | -526 K | - | -1.57 M | -2.02 M | -943 K | - | -835 K | -1.41 M | -71.1 K | - | -162 K | 47.5 K | 329 K | - | 436 K | 1.46 M | 168 K | - | 51.6 K | -53.6 K | -233 K | - | -540 K | -262 K | -122 K |
Interest Expense |
- | - | - | - | 1.52 K | 3.27 K | - | 8.01 K | 21 K | 24.5 K | - | 30.6 K | 48.7 K | 23.3 K | - | 28 K | 3.55 K | -4.74 K | - | -4.61 K | -4.46 K | -2.54 K | - | -569 | -4.06 K | -4.21 K | - | -2.63 K | -2.56 K | -2.26 K | - | -1.78 K | -1.76 K | -1.7 K | - | -1.05 K | -1.02 K | -1.21 K | - | 846 | -1 K | 1.24 K | - | 1.04 K | - | 1.21 K | - | - | - | -475 | - | 5.55 K | 30 K | 34.6 K | - | 36.5 K | 63.3 K | 42.4 K | - | 35.6 K | 34.7 K | 19.4 K |
EBITDA |
-1.47 M | -809 K | - | -1.11 M | -1.47 M | -1.98 M | - | -1.46 M | -1.77 M | -1.45 M | - | -1.49 M | -2.26 M | -1.33 M | - | -2 M | -2.87 M | -1.9 M | - | -1.96 M | -2.86 M | -963 K | - | -1.46 M | -3.15 M | -1.57 M | - | -921 K | -1.08 M | -792 K | - | -4.2 M | -1.18 M | -1.74 M | - | -1.25 M | -1.52 M | -491 K | - | -1.5 M | -1.97 M | -921 K | - | -815 K | -1.4 M | -65.4 K | - | -150 K | 54.5 K | 333 K | - | 449 K | 1.47 M | 172 K | - | 66.1 K | -43.6 K | -228 K | - | -524 K | -251 K | -116 K |
Operating Expenses |
3.1 M | 2.39 M | - | 2.78 M | 3.1 M | 3.65 M | - | 3.31 M | 3.19 M | 3.14 M | - | 3.01 M | 4.17 M | 3.23 M | - | 3.47 M | 3.57 M | 3.6 M | - | 3.34 M | 4.24 M | 2.79 M | - | 2.31 M | 3.28 M | 2.89 M | - | 2.32 M | 2.61 M | 2.12 M | - | 4.43 M | 2.83 M | 3.24 M | - | 3.22 M | 3.2 M | 2.81 M | - | 3.24 M | 3.6 M | 3.14 M | - | 2.5 M | 2.61 M | 1.91 M | - | 1.87 M | 1.55 M | 1.41 M | - | 1.33 M | 1.38 M | 1.51 M | - | 1.45 M | 1.53 M | 1.49 M | - | 1.69 M | 1.86 M | 1.67 M |
General and Administrative Expenses |
3.03 M | 2.37 M | - | 2.74 M | 3.03 M | 3.26 M | - | 3.06 M | 2.87 M | 3.04 M | - | 2.82 M | 3.94 M | 3.07 M | - | 3.28 M | 3.28 M | 3.12 M | - | 2.97 M | 4.01 M | 2.75 M | - | 2.28 M | 3.16 M | 2.75 M | - | 2.31 M | 2.52 M | 2.11 M | - | 2.89 M | 2.82 M | 3.02 M | - | 3.21 M | 3.08 M | 2.71 M | - | 2.93 M | 3.29 M | 3 M | - | 2.48 M | 2.59 M | 1.9 M | - | 1.84 M | 1.52 M | 1.39 M | - | 1.32 M | 1.34 M | 1.39 M | - | 1.39 M | 1.49 M | 1.45 M | - | 1.7 M | 1.8 M | 1.62 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Milestone Scientific (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M |  USA |
 |
Haemonetics Corporation
HAE
|
$ 102.85 | 0.95 % | $ 4.85 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Microbot Medical
MBOT
|
$ 1.44 | 0.34 % | $ 65.9 M |  Israel |
 |
The Cooper Companies
COO
|
$ 70.64 | 1.31 % | $ 14.1 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Repligen Corporation
RGEN
|
$ 169.61 | 1.72 % | $ 9.54 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
AtriCure
ATRC
|
$ 52.46 | 7.5 % | $ 2.5 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 180.35 | 0.46 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.0 | 0.06 % | $ 355 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 23.58 | 2.01 % | $ 1.17 B | USA |
 |
STERIS plc
STE
|
$ 226.83 | 0.83 % | $ 22.3 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 123.43 | 0.77 % | $ 3.95 B | USA |
 |
AngioDynamics
ANGO
|
$ 15.47 | 0.09 % | $ 642 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
ICU Medical
ICUI
|
$ 166.29 | 0.07 % | $ 4.1 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 12.18 | 0.33 % | $ 252 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 88.57 | 0.24 % | $ 5.24 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 27.59 | 0.73 % | $ 4.64 B | USA |
 |
Pro-Dex
PDEX
|
$ 61.75 | 1.92 % | $ 203 B | USA |
 |
Baxter International
BAX
|
$ 25.57 | 0.86 % | $ 13.1 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 54.71 | 3.85 % | $ 3.69 B | USA |
 |
Stereotaxis
STXS
|
$ 1.39 | 0.72 % | $ 126 M | USA |
 |
ResMed
RMD
|
$ 229.19 | 0.12 % | $ 33.4 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 369.83 | 0.28 % | $ 132 B | USA |
 |
electroCore
ECOR
|
$ 9.21 | 2.03 % | $ 78.1 K | USA |
 |
West Pharmaceutical Services
WST
|
$ 342.73 | 0.03 % | $ 24.8 B | USA |
 |
BioLife Solutions
BLFS
|
$ 35.53 | 1.27 % | $ 1.7 B | USA |
 |
Alcon
ALC
|
$ 72.08 | 0.3 % | $ 35.5 B |  Schweiz |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.43 | 1.24 % | $ 2.28 B | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.22 | 1.21 % | $ 149 M | USA |
 |
Nephros
NEPH
|
$ 4.18 | 0.95 % | $ 44.4 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 80.49 | 0.22 % | $ 1.82 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.58 | 2.27 % | $ 263 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 187.62 | 0.05 % | $ 54 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.71 | 1.24 % | $ 21.3 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 139.96 | 0.35 % | $ 6.25 B | USA |
 |
Utah Medical Products
UTMD
|
$ 70.71 | 0.05 % | $ 229 M | USA |